Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

The Risks of Prediabetes

Is a Plant-Based Diet Good for Type 2 Diabetes?

Living With Type 2 Diabetes

Type 2 Diabetes Symptoms

Fibromyalgia and Diabetes

Insulin Resistance Diagnosis

Insulin Medication

Type 2 Diabetes Diagnosis

What is Diabetes?

Diabetes Mellitus Type 2 Pathophysiology

Diabetes in Men versus Women

See more featured articles »

Type 2 Diabetes Screening and Prevention

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Insulin Resistance Pathophysiology

Insulin Resistance Symptoms

Type 2 Diabetes Treatment

Insulin Resistance Treatment

Vitamin D and Type 2 Diabetes

What is Insulin Resistance?

Causes of Insulin Resistance

Does the Keto Diet Increase the Risk of Diabetes?

Insulin Resistance and Parkinson's Disease

Latest Type 2 Diabetes News and Research

Seven hours sleep linked to lower insulin resistance risk

Sleeping for 7 hours and 18 minutes every night may be the sweet spot for warding off the risk of insulin resistance-the precursor to type 2 diabetes-suggests a large observational study published in the open access journal BMJ Open Diabetes Research & Care.

3 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Weight-loss drugs may reduce heart damage after heart attack

Weight-loss (GLP-1 mimicking) drugs may help prevent further tissue damage following a heart attack, significantly reducing the risk of further life-threatening complications that affect up to half of all patients, according to a new study led by the University of Bristol and University College London.

2 Mar 2026

Poor oral health in childhood linked to higher incidence of cardiovascular disease in adulthood

A tooth cavity and bleeding gums is a common scenario among Danish children – and one that researchers now connect to health problems long after the last baby tooth has left the mouth.

2 Mar 2026

Living in deprived neighborhoods reshapes the gut microbiome

This study reveals links between socioeconomic deprivation and gut microbiome changes, highlighting potential pathways to mental and metabolic health issues.

2 Mar 2026

Higher tyrosine levels linked to shorter lifespan in major UK Biobank analysis

Researchers analyzed over 272,000 UK Biobank participants and used Mendelian randomization to investigate whether circulating phenylalanine and tyrosine influence lifespan. Genetically predicted higher tyrosine levels were linked to shorter lifespan, particularly in men, while phenylalanine showed no independent effect after adjustment.

1 Mar 2026

Colorful japonica rice varieties show unique health-promoting lipids

Rice feeds more than half of the world's population, yet we still only partly understand the nutrients it contains.

27 Feb 2026

How physical strength and self-belief grow together in teens

Physical fitness and psychological resilience develop side by side during adolescence, a life stage that lays the foundation for adult health. Cardiorespiratory endurance, muscular strength, and agility are well-known predictors of cardiometabolic health, while self-efficacy, defined as the belief in one's ability to overcome challenges, shapes motivation, persistence, and coping strategies.

26 Feb 2026

New review explains how circular RNAs could unlock fat browning therapies

A Cell Death & Disease review synthesizes preclinical evidence that circular RNAs regulate adipose browning and metabolic pathways through microRNA interactions, protein binding, and organelle-linked stress mechanisms. It highlights their biomarker and therapeutic potential in obesity and type 2 diabetes while underscoring key translational challenges, including delivery specificity and human validation.

26 Feb 2026

Heavy alcohol intake is associated with dangerous belly fat accumulation, large UK study shows

In a large UK population cohort, higher weekly alcohol consumption was dose-dependently associated with greater visceral fat mass measured by DXA, independent of total body fat. Heavy drinkers showed over 10% higher proportional visceral fat compared with lower consumption groups, a pattern linked to increased cardiometabolic risk.

26 Feb 2026

Combining healthy lifestyle and GLP-1 therapy reduces heart risks in diabetes

Individuals living with type 2 diabetes (T2D) had a significantly lower risk of poor cardiovascular health when they used a GLP-1 receptor agonist (GLP-1 RA) in combination with adhering to healthy lifestyle habits, according to a new study led by researchers at Harvard T.H. Chan School of Public Health and the Department of Veterans Affairs Boston Healthcare System.

25 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years.

24 Feb 2026

Higher ultra-processed food intake aligns with greater binge eating risk in obesity study

Higher intake of ultra-processed foods in adults with obesity was associated with disordered eating symptoms, poorer diet quality, and lower protein intake. The cross-sectional findings suggest dietary processing level may influence eating behaviour patterns relevant to obesity management, though causality cannot be inferred.

23 Feb 2026

Researchers show red blood cells drive better glucose tolerance at high altitude

Chronic hypoxia improves glucose tolerance in mice through insulin-independent mechanisms, with red blood cells acting as a major systemic glucose sink. Increased erythrocyte production and altered glycolytic flux help reduce circulating glucose while supporting oxygen delivery to tissues.

22 Feb 2026

Mounjaro ingredient shows promise in lowering alcohol consumption

For the first time, researchers show that tirzepatide - the active ingredient in the diabetes and weight-loss drug Mounjaro - reduces alcohol intake as well as relapse-like behaviors in rats and mice.

20 Feb 2026

Cyborg transplants may advance cell-based therapies for diabetes

A new electronic implant system can help lab‑grown pancreatic cells mature and function properly, potentially providing a basis for novel, cell-based therapies for diabetes.

19 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Gut bacteria patterns help predict insulin resistance in type 2 diabetes, study finds

Researchers used 16S rRNA sequencing and machine learning to identify gut microbiome patterns associated with insulin resistance severity in people with type 2 diabetes. XGBoost models showed that specific bacterial genera, including Bacteroides and Faecalibacterium, help distinguish individuals with higher insulin resistance from healthy controls.

19 Feb 2026

Monthly produce prescriptions do not improve blood sugar

Findings from a study on produce prescriptions show no significant improvement in blood sugar control, emphasizing the importance of addressing food insecurity.

19 Feb 2026